Health In Tech Reports Q1 Revenue Beat, Reiterates 2026 Guidance
HIT has more than doubled off its 52-week low of $0.555.
Summary
Health In Tech announced its first-quarter 2026 financial results, reporting revenues of $8.8 million, which surpassed analyst expectations, and reiterated its full-year 2026 revenue guidance.
Key Events · Earnings and Guidance · HIT
-
Q1 2026 Revenue Exceeds Expectations
Health In Tech reported first-quarter 2026 revenue of $8.8 million, a 9.4% increase from $8.0 million in Q1 2025, and notably higher than the $7.35 million expected by analysts.
-
Net Loss and Negative Adjusted EBITDA
The company reported a net loss of $1.6 million, or $(0.03) per diluted share, in line with analyst expectations, compared to net income of $0.5 million in Q1 2025. Adjusted EBITDA was $(1.3) million, down from $1.2 million in Q1 2025, reflecting higher growth-related expenses.
-
2026 Revenue Guidance Reiterated
Health In Tech reiterated its full-year 2026 revenue guidance of $45 million to $50 million, representing 35% to 50% year-over-year growth.
-
Improved Cash Position
Cash and cash equivalents increased to $10.3 million as of March 31, 2026, up from $7.6 million as of March 31, 2025, partly due to a $7 million PIPE financing completed in March.
Analysis · HIT · Finance
Health In Tech reported first-quarter 2026 financial results, exceeding analyst revenue expectations. While the company posted a net loss and negative Adjusted EBITDA for the quarter, attributed to increased sales and marketing expenses for growth initiatives, it reiterated its full-year 2026 revenue guidance. The revenue beat against expectations could provide a positive signal to investors, despite the decline in profitability compared to the prior year.
At the time of this filing, HIT was trading at $1.57 on NASDAQ in the Finance sector, with a market capitalization of approximately $87.9M. The 52-week trading range was $0.56 to $4.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.